Peer-reviewed veterinary case report
CD44 and CD24 protein levels linked to dog mammary tumor outcomes
By Rogez, Bernadette et al.·Published in Veterinary pathology·2019·1 University of Lille, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: CD44 and CD24 Expression and Prognostic Significance in Canine Mammary Tumors.
- Species:
- dog
Plain-English summary
A study looked at 96 dogs with mammary tumors to see how certain markers (CD44 and CD24) could help predict their survival. They found that a specific combination of these markers (CD44/CD24 phenotype) was linked to better overall survival, especially in a type of tumor called tubular complex carcinoma. However, CD24 alone was found in many tumors and was associated with worse outcomes. This suggests that while CD44/CD24 might indicate a better prognosis, CD24 could be a sign of poor prognosis in dogs with mammary cancer. More research is needed to confirm these findings.
People also search for: dog mammary tumor prognosis · canine mammary cancer treatment · CD24 marker in dogs
Abstract
CD44/CD24phenotype has been used to identify human and canine mammary cancer stem-like cells. In canine mammary tumors, CD44/CD24phenotype has been associated with high grade and lymph node infiltration. However, several studies have reported opposing results regarding the clinical significance of phenotypic groups formed by the combination of CD44 and CD24 in both human and canine mammary tumors. So far, no study has investigated the correlation between these phenotypes and survival in dogs. The aim of this study was to investigate the expression and distribution of CD44 and CD24 in canine mammary carcinomas and to correlate them with histological diagnosis and survival in a well-characterized cohort. Immunohistochemistry was performed in 96 mammary carcinomas with antibodies against CD44 and CD24. Expression of CD44and CD44/CD24phenotype was detected in 75 of 96 (78%) and 63 of 96 (65.6%) carcinomas, respectively. Their expression was associated with tumor type, occurring more often in tubular complex carcinomas than in solid carcinomas. CD44/CD24phenotype was associated with a better overall survival ( P = .001). CD24expression was detected in 52 of 96 tumors (54%) and CD44/CD24phenotype in 39 of 96 tumors (40.6%). Both were associated with poor clinicopathological parameters (high grade, and emboli). No correlation with overall survival was observed. CD44/CD24expression was associated with a better prognosis and occurred at high frequency and high level, indicating that this phenotype is not suitable to detect cancer stem cells in canine mammary carcinomas. Although further studies are needed, our results suggest that CD24 may constitute a valuable marker of poor prognosis for canine mammary carcinomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30558511/